

Baxter International Inc.
Reclassified Key Product Line Sales -- US/International
2006, 2005 & 2004¹
(unaudited)
(\$ in millions)

2006 Sales															
	Q1 2006			Q2 2006			Q3 2006			Q4 2006			Total 2006		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
Reclassified BioScience															
Recombinants ²	\$161	\$174	\$335	\$194	\$200	\$394	\$182	\$207	\$389	\$191	\$214	\$405	\$728	\$795	\$1,523
Plasma Proteins ³	67	125	192	87	126	213	87	127	214	102	160	262	343	538	881
Antibody Therapy	139	44	183	148	51	199	146	50	196	158	49	207	591	194	785
BioSurgery	39	30	69	44	35	79	40	32	72	43	35	78	166	132	298
Other ⁴	12	85	97	6	104	110	13	83	96	15	75	90	46	347	393
Total BioScience ⁵	\$418	\$458	\$876	\$479	\$516	\$995	\$468	\$499	\$967	\$509	\$533	\$1,042	\$1,874	\$2,006	\$3,880
Reclassified Medication Delivery															
IV Therapies ⁶	\$104	\$200	\$304	\$108	\$215	\$323	\$103	\$214	\$317	\$113	\$228	\$341	\$428	\$857	\$1,285
Global Injectables ⁷	225	128	353	244	132	376	210	140	350	234	140	374	913	540	1,453
Infusion Systems	124	71	195	123	81	204	118	79	197	132	89	221	497	320	817
Anesthesia ⁸	33	21	54	69	26	95	53	23	76	64	28	92	219	98	317
Other ⁹	5	5	10	8	6	14	5	5	10	6	5	11	24	21	45
Total Medication Delivery	\$491	\$425	\$916	\$552	\$460	\$1,012	\$489	\$461	\$950	\$549	\$490	\$1,039	\$2,081	\$1,836	\$3,917
Renal															
PD Therapy	\$66	\$322	\$388	\$68	\$340	\$408	\$67	\$342	\$409	\$67	\$362	\$429	\$268	\$1,366	\$1,634
HD Therapy	28	77	105	29	79	108	28	82	110	28	80	108	113	318	431
Total Renal	\$94	\$399	\$493	\$97	\$419	\$516	\$95	\$424	\$519	\$95	\$442	\$537	\$381	\$1,684	\$2,065
Transfusion Therapies ¹⁰															
	\$56	\$68	\$124	\$59	\$67	\$126	\$60	\$61	\$121	\$78	\$67	\$145	\$253	\$263	\$516
TOTAL BAXTER	\$1,059	\$1,350	\$2,409	\$1,187	\$1,462	\$2,649	\$1,112	\$1,445	\$2,557	\$1,231	\$1,532	\$2,763	\$4,589	\$5,789	\$10,378

2005 Sales															
	Q1 2005			Q2 2005			Q3 2005			Q4 2005			Total 2005		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
Reclassified BioScience															
Recombinants ²	\$145	\$162	\$307	\$170	\$186	\$356	\$170	\$181	\$351	\$168	\$185	\$353	\$653	\$714	\$1,367
Plasma Proteins ³	48	122	170	55	115	170	61	115	176	72	121	193	236	473	709
Antibody Therapy	48	41	89	50	43	93	83	40	123	103	44	147	284	168	452
BioSurgery	35	31	66	38	32	70	35	28	63	39	28	67	147	119	266
Other ⁴	57	80	137	57	104	161	34	69	103	30	80	110	178	333	511
Total BioScience ⁵	\$333	\$436	\$769	\$370	\$480	\$850	\$383	\$433	\$816	\$412	\$458	\$870	\$1,498	\$1,807	\$3,305
Reclassified Medication Delivery															
IV Therapies ⁶	\$94	\$202	\$296	\$98	\$214	\$312	\$101	\$200	\$301	\$109	\$207	\$316	\$402	\$823	\$1,225
Global Injectables ⁷	276	118	394	290	135	425	247	129	376	239	134	373	1,052	516	1,568
Infusion Systems	155	75	230	163	82	245	118	66	184	123	71	194	559	294	853
Anesthesia ⁸	21	20	41	62	21	83	57	18	75	55	17	72	195	76	271
Other ⁹	6	11	17	6	12	18	8	13	21	6	11	17	26	47	73
Total Medication Delivery	\$552	\$426	\$978	\$619	\$464	\$1,083	\$531	\$426	\$957	\$532	\$440	\$972	\$2,234	\$1,756	\$3,990
Renal															
PD Therapy	\$62	\$315	\$377	\$65	\$325	\$390	\$66	\$320	\$386	\$65	\$335	\$400	\$258	\$1,295	\$1,553
HD Therapy	32	94	126	34	80	114	30	75	105	31	78	109	127	327	454
Total Renal	\$94	\$409	\$503	\$99	\$405	\$504	\$96	\$395	\$491	\$96	\$413	\$509	\$385	\$1,622	\$2,007
Transfusion Therapies ¹⁰	\$65	\$68	\$133	\$68	\$72	\$140	\$66	\$68	\$134	\$67	\$73	\$140	\$266	\$281	\$547
TOTAL BAXTER	\$1,044	\$1,339	\$2,383	\$1,156	\$1,421	\$2,577	\$1,076	\$1,322	\$2,398	\$1,107	\$1,384	\$2,491	\$4,383	\$5,466	\$9,849

2004 Sales															
	Q1 2004			Q2 2004			Q3 2004			Q4 December			Total 2004		
	US	International	Total	US	International	Total	US	International	Total	US	International	Total	US	International	Total
Reclassified BioScience															
Recombinants ²	\$141	\$117	\$258	\$146	\$143	\$289	\$153	\$153	\$306	\$173	\$167	\$340	\$613	\$580	\$1,193
Plasma Proteins ³	43	102	145	47	122	169	63	99	162	45	134	179	198	457	655
Antibody Therapy	43	37	80	53	37	90	49	33	82	46	38	84	191	145	336
BioSurgery	27	26	53	32	27	59	31	24	55	33	29	62	123	106	229
Other ⁴	66	68	134	60	90	150	50	70	120	75	62	137	251	290	541
Total BioScience ⁵	\$320	\$350	\$670	\$338	\$419	\$757	\$346	\$379	\$725	\$372	\$430	\$802	\$1,376	\$1,578	\$2,954
Reclassified Medication Delivery															
IV Therapies ⁶	\$103	\$179	\$282	\$99	\$189	\$288	\$93	\$182	\$275	\$104	\$205	\$309	\$399	\$755	\$1,154
Global Injectables ⁷	268	113	381	296	114	410	248	114	362	345	121	466	1,157	462	1,619
Infusion Systems	126	62	188	159	74	233	179	69	248	184	75	259	648	280	928
Anesthesia ⁸	29	20	49	31	20	51	68	16	84	55	19	74	183	75	258
Other ⁹	8	18	26	4	20	24	5	12	17	6	15	21	23	65	88
Total Medication Delivery	\$534	\$392	\$926	\$589	\$417	\$1,006	\$593	\$393	\$986	\$694	\$435	\$1,129	\$2,410	\$1,637	\$4,047
Renal															
PD Therapy	\$66	\$283	\$349	\$70	\$292	\$362	\$65	\$297	\$362	\$68	\$318	\$386	\$269	\$1,190	\$1,459
HD Therapy	34	90	124	32	86	118	36	87	123	35	99	134	137	362	499
Total Renal	\$100	\$373	\$473	\$102	\$378	\$480	\$101	\$384	\$485	\$103	\$417	\$520	\$406	\$1,552	\$1,958
Transfusion Therapies ¹⁰	\$65	\$75	\$140	\$65	\$71	\$136	\$62	\$62	\$124	\$76	\$74	\$150	\$268	\$282	\$550
TOTAL BAXTER	\$1,019	\$1,190	\$2,209	\$1,094	\$1,285	\$2,379	\$1,102	\$1,218	\$2,320	\$1,245	\$1,356	\$2,601	\$4,460	\$5,049	\$9,509

¹Sales in 2006, 2005 and 2004 have been reclassified to reflect the changes that are described in notes 2, 4, 5, 7, 8 and 10 below.

²Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE). Sales of recombinant FIX (BeneFIX)

were previously reported in Recombinants and are now reported in Other, as detailed below.

³Includes plasma-derived hemophillia (FVII, FVIII, FIX and FEIBA), albumin and certain other plasma-based products.

⁴Primarily includes vaccines, sales of plasma to third parties, recombinant FIX (BeneFIX), and in 2005 and 2004, sales related to contract manufacturing. Recombinant FIX sales were previously reported in Recombinants.

⁵BioScience sales have been reclassified to reflect the change described in note 10.

⁶Primarily includes intravenous solutions and nutritional products.

⁷Primarily includes sales related to pharma partnering business, enhanced packaging, premix drugs and generic injectables. Generic injectables were previously reported in Anesthesia.

⁸Primarily includes proprietary inhaled anesthetics and other anesthesia products. Sales of generic injectables were previously reported in Anesthesia and are now reported in Global Injectables.

⁹Primarily includes other hospital-distributed products.

¹⁰Sales of Transfusion Therapies products were previously reported in BioScience.